Dr. Niti Raizada

Cancer, with its intricate molecular landscape and diverse manifestations, presents a formidable challenge. Traditional approaches to cancer treatment often rely on a one-size-fits-all strategy, which may not fully address the unique characteristics of each patient’s cancer. This is where multi-omics enters the spotlight, offering a comprehensive and personalised approach to understanding and treating cancer. Let’s delve into the fascinating world of multi-omics and its implications for revolutionising cancer care.

Multi-omics refers to the integration of multiple “omics” technologies, including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, to comprehensively analyse biological systems. Each omics layer provides unique insights into the molecular mechanisms underlying cancer development, progression, and response to treatment. By combining these layers of information, multi-omics approaches offer a holistic view of cancer biology.


Genomics: The Blueprint of Cancer: Genomics focuses on studying the complete set of genes (genome) within cancer cells. Through genomic sequencing, researchers can identify genetic alterations, such as mutations, amplifications, and deletions, that drive tumorigenesis. These genomic profiles not only aid in cancer diagnosis but also guide treatment decisions by identifying actionable targets, such as oncogenes or tumour suppressor genes. These are vital information in cancers like lung, bile duct etc and completely change the way we treat such cancers. Newer drugs are highly effective on actionable targetable gene mutations like EGFR, IDH1, ALK etc. TCGA (The Complete Genomic Atlas) was the very first effort to re-classify cancers based on genomic profiling and has led to an entire relook of cancer causation and treatment.

Transcriptomics: Decoding Gene Expression: Transcriptomics examines the expression levels transcriptome within cancer cells. By analysing RNA transcripts, researchers gain insights into which genes are active or inactive in cancer cells. This information is valuable for understanding cellular pathways, identifying biomarkers, and predicting treatment response. Certain newer drugs like NTRK targets require looking for transcriptomes.

Proteomics: Unveiling Protein Signatures: Proteomics focuses on studying the complete set of large scale study of proteins (proteome). Proteins play crucial roles in cell signalling, metabolism, and regulatory processes. Proteomic analyses can reveal proteomic molecular signatures associated with specific cancer subtypes, disease progression, and therapeutic targets.


Metabolomics: Profiling Metabolic Pathways: Metabolomics investigates the small molecules (metabolites) involved in cellular metabolism within cancer cells. Alterations in metabolic pathways are a hallmark of cancer, and metabolomic profiling can identify metabolic signatures associated with tumorigenesis, drug resistance, and metabolic vulnerabilities that can be targeted therapeutically.

Epigenomics :Epigenetic Modifications: Epigenomics explores the heritable changes in gene expression that are not due to alterations in the DNA sequence itself. Epigenetic modifications, such as DNA methylation and histone modifications, play critical roles in regulating gene expression in cancer cells. Epigenomic analyses provide insights into epigenetic alterations driving cancer development and progression.

The Power of Integration: The true strength of multi-omics lies in its ability to integrate data from these diverse omics layers, creating a comprehensive molecular profile of cancer. Integrative analyses can uncover complex interactions between genomic alterations, gene expression patterns, protein dynamics, metabolic changes, and epigenetic modifications. The complex data we have, requires use of artificial Intelligence, machine learning and bioinformatics to integrate the information and present “Biomarkers” which can be useful in clinical practice. This holistic approach enables researchers and clinicians to identify novel therapeutic targets, predict treatment response, and tailor precision therapies based on each patient’s molecular profile.

Multi-omics thus has far-reaching implications across the cancer care continuum:

  • Personalised Medicine: Multi-omics approaches facilitate the identification of personalised therapeutic targets and treatment strategies based on the molecular characteristics of each patient’s cancer. This precision medicine approach maximises treatment efficacy while minimising side effects.
  • Predictive Biomarkers: Integrative omics analyses identify predictive biomarkers that can anticipate treatment response or resistance. These biomarkers guide treatment decisions, monitor disease progression, and inform adjustments in therapy to optimise patient outcomes.
  • Early Detection and Diagnosis: Multi-omics technologies contribute to early cancer detection by identifying molecular signatures associated with pre-cancerous lesions or early-stage tumours. This early intervention improves prognosis and enhances survival rates.
  • Monitoring Treatment Response: By monitoring changes in omics profiles over time, clinicians can assess treatment response, detect emerging resistance mechanisms, and adapt treatment plans accordingly. This dynamic monitoring improves patient outcomes and reduces the risk of disease recurrence. Molecular monitoring is also emerging as a useful tool in cancers like colorectal, lung etc to look for early responders and early progressors based on circulating tumour DNA measurements.

Despite its immense potential, multi-omics integration faces challenges such as data standardisation, computational complexity, and cost-effectiveness. Addressing these challenges requires collaborative efforts among researchers, healthcare professionals, and technology innovators. Future advancements in omics technologies, bioinformatics tools, and data analytics will further enhance the utility of multi-omics in cancer care.

Multi-omics represents a paradigm shift in cancer research and clinical practice, offering a comprehensive and personalised approach to understanding cancer biology and improving patient care. By integrating genomic, transcriptomic, proteomic, metabolomic, and epigenomic data, multi-omics analyses unlock new insights into cancer pathogenesis, treatment response, and therapeutic opportunities. As multi-omics technologies continue to evolve, they hold the promise of transforming cancer care, leading to more effective treatments, better outcomes, and ultimately, a brighter future for cancer patients.

Views expressed by Dr. Niti Raizada, Senior Director, Medical Oncology & Haemato-Oncology, Fortis Group of Hospitals, Bangalore


Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related Article


whatsapp--v1